Home › Non-Muscle Invasive Bladder Cancer › District of Columbia
Non-Muscle Invasive Bladder Cancer clinical trials in District of Columbia
4 studies for Non-Muscle Invasive Bladder Cancer are looking for participants at sites in District of Columbia.
Cities in District of Columbia
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- Sibley Memorial Hospital, Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07000084LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- The George Washington Medical Faculty Associates, Washington D.C.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT04752722Blue Light Cystoscopy With Cysview® Registry
- Sibley Memorial Hospital, Washington D.C.
RecruitingObservational study
Ages 18 and older · All sexes · Updated Dec 18, 2025 · NCT02660645Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
- Sibley Memorial Hospital, Washington D.C.
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 18, 2025 · NCT05672615From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.